Bronchitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Bronchitis - Pipeline Review, H2 2014', provides an overview of the Bronchitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bronchitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bronchitis Overview 6 Therapeutics Development 7 Pipeline Products for Bronchitis - Overview 7 Pipeline Products for Bronchitis - Comparative Analysis 8 Bronchitis - Therapeutics under Development by Companies 9 Bronchitis - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Bronchitis - Products under Development by Companies 12 Bronchitis - Companies Involved in Therapeutics Development 13 DBV Technologies S.A. 13 Hyundai Pharmaceutical Co., Ltd. 14 Mucosis B.V. 15 Myelo Therapeutics GmbH 16 Pacific Therapeutics Ltd. 17 PARI Pharma GmbH 18 Recipharm AB 19 Bronchitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 (pentoxifylline + acetylcysteine) - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 cyclosporine liposomal - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 erdosteine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 HOB-051 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Myelo-001 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 nitric oxide - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RSV vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 SynGEM - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Bronchitis - Recent Pipeline Updates 40 Bronchitis - Dormant Projects 43 Bronchitis - Discontinued Products 44 Bronchitis - Product Development Milestones 45 Featured News & Press Releases 45 Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 45 Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 45 Nov 13, 2012: Pacific Therapeutics Announces Positive Results From Phase I Trial Of PTL-202 46 Aug 22, 2012: Pacific Therapeutics Completes Enrollment In Clinical Trial Of PTL-202 46 Jan 10, 2012: Pacific Therapeutics Provides Update On Development Of Lead Drug Candidate, PTL-202 47 Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 47 Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Bronchitis, H2 2014 7 Number of Products under Development for Bronchitis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Bronchitis - Pipeline by DBV Technologies S.A., H2 2014 13 Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014 14 Bronchitis - Pipeline by Mucosis B.V., H2 2014 15 Bronchitis - Pipeline by Myelo Therapeutics GmbH, H2 2014 16 Bronchitis - Pipeline by Pacific Therapeutics Ltd., H2 2014 17 Bronchitis - Pipeline by PARI Pharma GmbH, H2 2014 18 Bronchitis - Pipeline by Recipharm AB, H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Assessment by Combination Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 29 Bronchitis Therapeutics - Recent Pipeline Updates, H2 2014 40 Bronchitis - Dormant Projects, H2 2014 43 Bronchitis - Discontinued Products, H2 2014 44
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.